Molecular docking investigations of new glycosides with potential anticancer activities

Cancer is recognized as one of the most common fatal diseases of mankind, described as the uncontrolled growth and spread of abnormal cells, it has recently become one of the leading causes of death. Some agents used in the treatment of cancer (chemotherapy) cause numerous side effects due to their cytotoxic and mutagenic effects on healthy cells. This aroused interest on the part of the scientific community for the development of alternative drugs that do not have side effects, that are effective and selective. In recent years molecular hybridization has gained prominence, this technique consists of combining two or more bioactive pharmacophores to obtain a single molecule. Recently, using this approach, researchers have reported the synthesis of glycosides coupled to biologically active heterocyclics, showing an improvement in the pharmacological properties and bioavailability of the compounds, contributing to the water solubility and stability of organic molecules. In this study, molecular docking simulations carried out in two articles will be analyzed: “Design, synthesis, anticancer activity and molecular anchorage of new glycosides based on 1,2,3- triazole containing 1,3,4-thiadiazlil, indolyl and scaffolds of arylacetamide” and “New pyridines-N-βD-glycosides: synthesis, biological evaluation, and molecular docking investigations”, by the respective authors, Hussein H. Elganzory and Nuran Kahriman, for analysis of the software used in molecular editors and descriptors , database and ligand-receptor docking.